News AZ's immunotherapy combo misses the mark in untreated lung c... AstraZeneca’s immunotherapy combination has missed the mark in certain patients with untreated lung cancer, failing to improve survival compared with standard chemotherapy in a phase 3 tria
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.